PMID- 33078904
OWN - NLM
STAT- MEDLINE
DCOM- 20210512
LR  - 20240330
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 24
IP  - 22
DP  - 2020 Nov
TI  - Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant 
      solid tumours: A systematic review.
PG  - 13494-13506
LID - 10.1111/jcmm.15991 [doi]
AB  - Treatment of multiple malignant solid tumours with programmed death (PD)-1/PD 
      ligand (PD-L) 1 inhibitors has been reported. However, the efficacy and immune 
      adverse effects of combination therapies are controversial. This meta-analysis 
      was performed with PubMed, Web of Science, Medline, EMBASE and Cochrane Library 
      from their inception until January 2020. Random-effect model was adopted because 
      of relatively high heterogeneity. We also calculated hazard ratio (HR) of 
      progression-free survival (PFS), overall survival (OS) and risk ratio (RR) of 
      adverse events (AEs), the incidence of grade 3-5 AEs by tumour subgroup, 
      therapeutic schedules and therapy lines. Nineteen articles were selected using 
      the search strategy for meta-analysis. Combined PD-1/PD-L1 inhibitors prolonged 
      OS and PFS (HR 0.72, P < 0.001) and (HR 0.66, P < 0.001). In addition, incidence 
      of all-grade and grade 3-5 AEs was not significant in the two subgroup analyses 
      (HR 1.01, P = 0.31) and (HR 1.10, P = 0.07), respectively. Our meta-analysis 
      indicated that combination therapy with PD-1/PD-L1 inhibitors had greater 
      clinical benefits and adverse events were not increased significantly.
CI  - (c) 2020 The Authors. Journal of Cellular and Molecular Medicine published by 
      Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
FAU - Yao, Qigu
AU  - Yao Q
AD  - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The 
      First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 
      City, China.
FAU - Gu, Lihu
AU  - Gu L
AD  - Department of General Surgery, HwaMei Hospital, University of Chinese Academy of 
      Sciences, Ningbo City, China.
FAU - Su, Rong
AU  - Su R
AD  - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The 
      First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 
      City, China.
FAU - Chen, Bangsheng
AU  - Chen B
AD  - Emergency Medical Center, The Second Hospital of Yinzhou, Ningbo City, China.
FAU - Cao, Hongcui
AU  - Cao H
AUID- ORCID: 0000-0002-6604-6867
AD  - State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The 
      First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 
      City, China.
AD  - Zhejiang Provincial Key Laboratory for Diagnosis and Treatment of Aging and 
      Physic-chemical Injury Diseases, Hangzhou City, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20201020
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD274 protein, human)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Programmed Cell Death 1 Receptor)
SB  - IM
MH  - Animals
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - B7-H1 Antigen/*antagonists & inhibitors
MH  - *Biomarkers, Tumor
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Humans
MH  - Immune Checkpoint Inhibitors/pharmacology/*therapeutic use
MH  - *Molecular Targeted Therapy/adverse effects/methods
MH  - Neoplasms/diagnosis/*drug therapy/etiology/mortality
MH  - Prognosis
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
MH  - Proportional Hazards Models
MH  - Publication Bias
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC7701512
OTO - NOTNLM
OT  - PD-1/PD-L1 inhibitors
OT  - adverse events
OT  - meta-analysis
OT  - solid tumours
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/10/21 06:00
MHDA- 2021/05/13 06:00
PMCR- 2020/11/01
CRDT- 2020/10/20 08:39
PHST- 2020/05/18 00:00 [received]
PHST- 2020/09/18 00:00 [revised]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/05/13 06:00 [medline]
PHST- 2020/10/20 08:39 [entrez]
PHST- 2020/11/01 00:00 [pmc-release]
AID - JCMM15991 [pii]
AID - 10.1111/jcmm.15991 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2020 Nov;24(22):13494-13506. doi: 10.1111/jcmm.15991. Epub 2020 
      Oct 20.